Home > News > Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
October 19th, 2004
Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy
Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that Insert is planning with City of Hope Comprehensive Cancer Center a broad-based Phase I clinical trial for Insert's lead drug candidate.
Source:
businesswire
Related Links |
Arrowhead Research Corporation
Related News Press |
Nanomedicine
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Announcements
New discovery aims to improve the design of microelectronic devices September 13th, 2024
New method in the fight against forever chemicals September 13th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||